ELAB
Elevai Labs, Inc. Common Stock
NASDAQ: ELAB · HEALTHCARE · BIOTECHNOLOGY
$2.53
-0.39% today
Updated 2026-04-29
Market cap
$11.08M
P/E ratio
—
P/S ratio
18.78x
EPS (TTM)
$-382.61
Dividend yield
—
52W range
$2 – $269
Volume
9.0M
Elevai Labs, Inc. Common Stock (ELAB) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
0 of 8
Last 8 quarters
Avg EPS surprise
—
Last 4 quarters
Revenue YoY growth
-42.3%
Most recent quarter
EPS YoY growth
+45.3%
Most recent quarter
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-6.2%
Last 3 reports
Positive reaction rate
0%
0 of 3 quarters
Largest single-day move
-9.1%
2025-09-22
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2025-12-31 | $-51.92 | — | $1.48 | $1.42 | -4.1% |
| 2025-11-14 | $-4.95 | — | $5.51 | $5.21 | -5.4% |
| 2025-09-22 | $-8.44 | — | $5.82 | $5.29 | -9.1% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | — | $-51.92 | — | $304136.00 | — |
| 2025-09-30 | — | $-4.95 | — | $285948.00 | -45.8% |
| 2025-06-30 | $0.00 | $-8.44 | — | — | — |
| 2025-03-31 | — | $-2.90 | — | $152381.00 | -75.2% |
| 2024-09-30 | — | $-94.85 | — | $527478.00 | — |
| 2024-06-30 | — | $-9,077.70 | — | $605529.00 | — |
| 2024-03-31 | — | $-9,481.84 | — | $614563.00 | — |
| 2023-12-31 | — | $-7,857.70 | — | $698591.00 | — |
Frequently asked questions
Has Elevai Labs, Inc. Common Stock beaten earnings estimates?
Elevai Labs, Inc. Common Stock has beaten Wall Street EPS estimates in 0 of its last 8 quarterly reports.
How does ELAB stock react to earnings?
ELAB stock has moved an average of -6.2% in the trading day following earnings over its last 3 reports, with positive reactions in 0% of those quarters.
What is Elevai Labs, Inc. Common Stock's revenue growth rate?
Elevai Labs, Inc. Common Stock reported year-over-year revenue growth of -42.3% in its most recent quarter, with EPS growing +45.3% year-over-year.